Iratumumab

Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) [1].

Product Specifications

CAS Number

[640735-09-7]

Product Name Alternative

MDX-060

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iratumumab.html

Purity

98.95

Solubility

10 mM in DMSO

Smiles

[Iratumumab]

Molecular Weight

(142.9 kDa)

References & Citations

[1]Ansell SM, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007 Jul 1;25 (19) :2764-9.